Kate Rochlin

Kate Rochlin

Company: IN8Bio

Job title: Chief Operating Officer


Gamma-Delta T cell non-signaling CAR (nsCAR) platform for selective tumor targeting 2:30 pm

INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform with ability to target cancer cells while sparing healthy tissue when both express the CARtargeted antigen. This is done by keeping the endogenous gamma-delta receptors intact and combining with a cell engaging nsCAR nsCAR platform leverages the ability of gamma-delta T cells to selectively target…Read more

day: Day Two

Cancelled: Going Beyond Traditional T-Cell Types: Clinical Assessment of Macrophages, NK Cells & Gamma Delta T-Cells 9:00 am

Discuss what the clinical evidence suggests when it comes to improving response rates with different cell types. Questioning if harnessing alternative cell types such as innate immune cell engagers or γδ T-Cells out beat the more traditional combination with PD1/PD-L1 in patients. Additionally, deep diving into how cell engagers have shown greater potential than any…Read more

day: Pre-Conference Day Track B

Noval Modalities: A Review 9:00 am - 12:00 pm

The three approved cell engager antibodies currently available all have different engagers, different targets and different formats. Indicating that there is no one specific playbook to follow. Additionally, this also evidences that there is a lot of innovation taking place in the space. In this session, we will see examples of these modalities and hear…Read more

day: Pre-Conference Day Track A

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.